Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
qBOLD MRI with Feraheme in GBM
NCT02466828Phase 1Completed
- Sponsor
- Sunnybrook Health Sciences Centre
- Start
- Mar 2015
- Primary completion
- Apr 2018
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ferumoxytol in glioblastoma (GBM), sponsored by Sunnybrook Health Sciences Centre. Primary endpoint: Oxygen saturation in GBM with qBOLD MRI and its correlation with histological markers of tissue hypoxia and angiogenesis. Started Mar 2015; status: completed.
02
Drugs
ferumoxytol
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02466828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02466828.